Viral Immunology · 2012 · 64 citations · 60 references
Life SciencesImmunologyInfectious DiseasesImmunizationImmunology Of Infectious DiseasesVaccinologyAntiviral ImmunityCell-mediated ImmunityImmune Response To VaccinationMolecular MimicryVaccinationViral VaccinesAdaptive Immune Responses To Viral InfectionAntibody-mediated Viral NeutralizationAntibody-mediated Virus NeutralizationCellular ChemotaxisCellular Immune Response To VirusesChemotaxisHost Immune Response ModulationRespiratory Syncytial Virus Vaccines
Respiratory syncytial virus (RSV) is a primary cause of severe lower respiratory tract disease in infants, young children, and the elderly worldwide, and despite decades of effort, there remains no safe and effective vaccine. RSV modifies the host immune response during infection by CX3C chemokine mimicry adversely affecting pulmonary leukocyte chemotaxis and CX3CR1+ RSV-specific T-cell responses. In this study we investigated whether immunization of mice with RSV G protein polypeptides from strain A2 could induce antibodies that block G protein-CX3CR1 interactions of both RSV A and B strains. The results show that mice immunized with RSV A2 G polypeptides generate antibodies that block binding of RSV A2 and B1 native G proteins to CX3CR1, and that these antibodies effectively cross-neutralize both A and B strains of RSV. These findings suggest that vaccines that induce RSV G protein-CX3CR1 blocking antibodies may provide a disease intervention strategy in the efforts to develop safe and efficacious RSV vaccines.
60
Two Distinct Subtypes of Human Respiratory Syncytial Virus
Maurice A. Mufson, Claes Örvell, Björg Rafnar et al. · Journal of General Virology · 1985 · 673 citations